Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib adjuvant therapy in resected stage II–IIIA NSCLC with uncommon EGFR mutations
ChiCTR2600122043Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: 2-year disease-free survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122043.